Key result
Transcatheter aortic valve implantation has become a common procedure for high or prohibitive surgical risk patients, with over 250,000 devices implanted worldwide.
Highlights the evolution and growing adoption of percutaneous treatments for valvular heart disease, particularly TAVI, as minimally invasive alternatives for high-risk patients.
Percutaneous treatments of valvular heart disease have evolved over the past two decades. These “minimally invasive” procedures are attractive alternatives to surgery for a growing high-risk population with multiple comorbidities. In 2002, Cribier et al. (1) performed the first transcatheter aortic valve implantation (TAVI) in a patient with aortic stenosis. Currently, TAVI has become a common procedure for high or prohibitive surgical risk patient and is moving rapidly into intermediate risk patients, with over 250,000 devices implanted worldwide.
No takes yet. Share an insight, caveat, or question.
Chamsi‐Pasha et al. (2017) conducted an editorial in Valvular heart disease. Percutaneous treatments of valvular heart disease was evaluated. Transcatheter aortic valve implantation has become a common procedure for high or prohibitive surgical risk patients, with over 250,000 devices implanted worldwide.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: